- “In 2024, over 611,000 deaths from cancer are projected for the U.S.,” the ACA reported. “That’s more than 1,600 deaths from cancer each day.”
- Calidi Biotherapeutics’ RTNova (“CLD-400”) is an innovative systemic antitumor enveloped virotherapy, designed to unlock new possibilities in cancer therapy.
- RTNova offers a systemic approach that enables providers to target and treat metastatic tumors that were previously untouchable.
The American Cancer Society (“ACA”) has projected that 2024 will be the first year ever to see two million people diagnosed with cancer, which remains the second leading cause of death in the United States, after heart disease (https://ibn.fm/ADo2Q). Companies such as Calidi Biotherapeutics (NYSE American: CLDI) are working hard to discover more effective treatments to curb the rising numbers. Calidi recently presented key data at two prominent scientific conferences regarding its new generation of targeted antitumor virotherapies and viral vectors (https://ibn.fm/9johm).
“Over the last 30 years, the risk of dying from cancer has steadily declined, sparing some four million lives in the United States,” the ACA reported. “This downward trend can partially be explained by big wins in smoking cessation, early cancer detection and treatment advancements. Cancer incidence, however, is on the rise for many common cancers. In the coming year, we’re expecting to hit a bleak milestone — the first time new cases of cancer in the U.S. are expected to cross the two-million mark. That’s almost 5,500 cancer diagnoses a day.”
The report noted that the upward trend is impacted by the aging and growth of the population and by a rise in diagnoses of six of the 10 most common cancers: breast, prostate, endometrial, pancreatic, kidney and melanoma. The other four top-10 cancers are lung, colon and rectum, bladder, and non-Hodgkin lymphoma.
“In 2024, over 611,000 deaths from cancer are projected for the U.S.,” the report stated. “That’s more than 1,600 deaths from cancer each day.”
Developing new and improved cancer therapies is essential to enhance patient outcomes, reduce side effects and address the complexities of different cancer types. Ground-breaking treatments can provide more effective personalized care, targeting tumors while sparing healthy cells. Advances in immunotherapy, targeted therapies and precision medicine hold the potential to transform cancer from a life-threatening disease to a manageable condition. Additionally, with cancer incidence rising globally, continued research and development are critical to meeting the growing demand for accessible, life-saving treatments and improving the quality of life for millions.
Calidi Biotherapeutics’ RTNova (“CLD-400”) is an innovative systemic antitumor enveloped virotherapy, designed to unlock new possibilities in cancer therapy. The platform addresses challenges presented by untargetable and untreatable metastatic diseases and offers a possible potential transformative solution with wide-ranging applications. The company shared key information about RTNova at two recent conferences: the International Oncolytic Virotherapy Conference (“IOVC”) in Rotterdam, Netherlands, which was held Oct. 27–30, 2024, and Immuno U.S. 2024 in San Diego, California, which was held Oct. 28–30. In addition, the company reported a poster featuring RTNova was presented at the annual meeting of the Society for Immunotherapy of Cancer (“SITC”), which was held in Houston Nov. 6–10.
RTNova is a systemic treatment designed for reduced elimination by the humoral immune system. It targets multiple tumor sites, killing tumor cells while altering the tumor immune microenvironment. This novel therapeutic approach not only facilitates easier administration but also broadens the potential patient population that can benefit from this treatment.
“RTNova represents a groundbreaking advancement in cancer therapy, offering a systemic approach that enables us to target and treat metastatic tumors that were previously untouchable,” said Antonio F. Santidrian, PhD., Calidi’s chief scientific officer. “RTNova’s ability to fundamentally change the tumor microenvironment while delivering therapeutic viruses to multiple tumor sites has the potential to unlock new possibilities for patients facing some of the most challenging cancers. Ultimately, we believe RTNova has the potential to transform how we address previously untreatable metastatic diseases.”
Calidi Biotherapeutics is a clinical-stage, immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi’s novel stem-cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi’s clinical-stage, off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify and potentiate oncolytic viruses, leading to enhanced efficacy and improved patient safety. Calidi’s preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach can potentially treat, or even prevent, metastatic disease.
For more information, visit www.CalidiBio.com.
NOTE TO INVESTORS: The latest news and updates relating to CLDI are available in the company’s newsroom at https://ibn.fm/CLDI
About QualityStocks
QualityStocks (“QS”) is a specialized communications platform with a focus on private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, QS is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, QS brings its clients unparalleled recognition and brand awareness. QS is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-published: https://www.QualityStocks.com/Disclaimer
QualityStocks
Scottsdale, AZ
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
QualityStocks is powered by IBN
